[Skip to Navigation]
June 27, 1959


Author Affiliations

New York

From the Department of Medicine and the Rheumatic Diseases Study Group, New York University College of Medicine and the Third Medical Division, Bellevue Hospital Center.

JAMA. 1959;170(9):1056-1062. doi:10.1001/jama.1959.63010090007011

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


Any discussion of therapy in rheumatic fever must, of course, be concerned with the extremely important aspect of prevention as well as with treatment of the attack which has already begun. The measures of importance in prevention can be stated with confidence in the light of progress made over the past 30 years. Unfortunately, however, one can write with far less certainty about the treatment of the established attack. In this presentation, both prevention and treatment will be considered and the evidence for and against the important unsettled issues will be briefly discussed. In addition, some aspects of the treatment of patients with inactive rheumatic heart disease will be included.

Prevention  The evidence that rheumatic fever does not occur without a preceding infection due to a group A hemolytic streptococcus is now so well established that it is necessary to mention only a few of the more important recent studies

First Page Preview View Large
First page PDF preview
First page PDF preview